Anti-tumour necrosis factor therapy for early-stage Dupuytren's disease (RIDD): a phase 2b, randomised, double-blind, placebo-controlled trial

    Press/Media: Expert CommentPopular

    Period29-Apr-2022

    Media coverage

    1

    Media coverage